Hansen PB. Differential effect of T-type voltage-gated Ca 2ϩ channel disruption on renal plasma flow and glomerular filtration rate in vivo.
THE REGULATION of renal blood flow, including renal medullary blood flow, and glomerular filtration pressure involves voltagegated Ca 2ϩ (Ca v ) channels, which mediate changes in pre-and postglomerular vessel diameters. These effects influence glomerular filtration rate (GFR) and salt and water homeostasis and thereby blood pressure.
Ca v channels are differentially expressed in the renal vasculature, as preglomerular vessels express L-type (Ca v 1.2) and T-type (Ca v 3.1 and Ca v 3.2) Ca 2ϩ channels, whereas postglomerular cortical efferent vessels are devoid of L-type Ca 2ϩ channels, but mouse efferent arterioles express T-type (Ca v 3.1 and Ca v 3.2) Ca 2ϩ channel subunits (17, 36) . In contrast, both L-type and T-type Ca 2ϩ channels are found in thick muscular juxtamedullary efferent arterioles, which control medullary perfusion (17) .
The involvement of T-type Ca 2ϩ channels in the regulation of microvascular diameter has been observed in both rat and mouse afferent and efferent arterioles (12, 17, 35, 36) , whereas L-type Ca 2ϩ channels are assumed not to play a role in cortical efferent arteriolar contractility (6, 17, 28, 31) . Wheras mouse studies have indicated a depolarization-induced effect in efferent arterioles, results from rats are less clear. Some studies have shown that Ca 2ϩ influx pathways in rat efferent vessels are not dependent on depolarization for the ANG II-induced contraction (24, 28, 29) , whereas others have shown that the T-type blockers mibefradil and nickel chloride affect the ANG II-elicited constriction in efferent arterioles of the isolated perfused hydronephrotic rat kidney model (21, 35) . Moreover, there appears to be regional differences in that juxtamedullary arterioles (and vasa recta) exhibit a larger dependence on depolarization compared with cortical efferent arterioles (17) . In vivo data from dogs treated with channel antagonists have confirmed the heterogeneity between afferent and efferent arterioles as well as an important contribution from T-type Ca 2ϩ channels in efferent arterioles (23, 42) . L-type antagonists led to an increased filtration fraction, corresponding to dilatation of afferent but not efferent arterioles, whereas T-type antagonists caused no increase in the filtration fraction (23) but a similar increase in renal blood flow as L-type antagonists. The contribution of T-type Ca 2ϩ channel activity to efferent constriction is likely supported by the Ca v 3.1 subtype (36) . The Ca v 3.2 subtype is involved in nitric oxide (NO)-dependent dilatation of efferent arterioles since Ca v 3.2 and endothelial NO synthase (eNOS) blockade inhibited the secondary dilatation after a depolarization-induced constriction of perfused efferent arterioles (36) . This is corroborated by the finding that Ca v 3.2-deficient mice exhibit normal vasoconstrictor responses in coronary arteries but reduced relaxation of coronary arterioles after the administration of ACh and nitroprusside (8) . Based on these in vitro observations and the intrarenal vascular distribution of Ca v 3 subtypes, it was hypothesized that disruption of Ca v 3.1 would increase renal blood flow but not alter GFR proportionally since it is expressed both in pre-and postglomerular vessels. On the other hand, targeting Ca v 3.2 would be predicted to increase vascular resistance and filtration fraction due to its preferential efferent localization and NOpromoting action in vitro.
Use of mice with targeted disruption of Ca v channels allows the investigation of the importance of T-type Ca 2ϩ channels without the question of drug specificity. (27) and C57BL/6J WT mice (Taconic Farm, Ry, Denmark) were used. C57BL/6J WT mice were used as controls as Cav3.1 Ϫ/Ϫ mice were backcrossed to a C57BL/6J background for Ͼ10 generations. Animals were 8 -10 wk of age and of both sexes. The experimental protocol was approved by the Danish Animal Experiments Inspectorate under the Danish Ministry of Food, Agriculture and Fisheries, and animal care followed guidelines of the National Institutes of Health.
Human material. The use of human material was approved by the Danish Ethical Committee, and kidney specimens were received from the Department of Urology at Odense University Hospital (Odense, Denmark). Renal blood vessels were isolated from patients who underwent nephrectomy for renal cancer and had given their informed written consent. Kidneys were extirpated, and intrarenal arteries (interlobar and arcuate arteries) were isolated from normal tissue (18) . The study included 13 patients, with the primary diagnoses being either malign or benign tumours. The age range was from 43-82 yr old with a mean of 64 Ϯ 3.4 yr and blood pressure of 138 Ϯ 6.1/86 Ϯ 4.2 mmHg.
Vascular responses and perfused mouse afferent and efferent arterioles. Mice were killed by cervical dislocation. Cortical afferent or efferent arterioles identified by appearance and location were microdissected and perfused as previously described (2) . In short, the arteriole was transferred to a temperature-controlled (37°C) chamber (Warner) containing DMEM-F-12 (saturated 5% CO 2 in air) with 0.1% BSA. The segment was perfused by aspiration of the arteriole into a holding pipette (tip diameter: 14 m) followed by cannulation with a perfusion pipette (tip diameters: 5 m for efferent arterioles and 7 m for afferent arterioles) and an increase in the driving pressure until the vessel opened (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . Experiments were performed using an inverted microscope system (Olympus), and the luminal diameter was measured at most reactive part of the arteriole determined at the first response to high K ϩ . All measurements were made at the same site of the arteriole. After the perfusion was established, all experimental protocols started with a period of equilibration, and vessel viability was tested by administration of high-K ϩ solution (100 mmol/l K ϩ ) added to the bath. Concentration-response curves were obtained for increasing concentrations of K ϩ in the range of 10, 15, 30, 55, and 75 mmol/l. Each concentration was applied for 3 min in the presence of phentolamine (10 Ϫ5 mol/l) to exclude nerve-mediated ␣-adrenergic effects of depolarization. Finally, the contractile response to increasing concentrations of U-46619 and ANG II was tested in afferent arterioles.
High-K ϩ solution contained (in mM) 45 NaCl, 70 KCl, 25 NaHCO3, 1.2 MgSO4, 2.5 K2HPO4, 1.3 CaCl2, 5.5 glucose, and 10 HEPES. Solutions were equilibrated with 5% CO2 in air, resulting in pH 7.4 with 0.1% and 1% BSA superfusate and perfusate, respectively.
Vascular responses and isometric force measurements in intrarenal human arteries. Human intrarenal arteries were isolated under a stereomicroscope and stored at 4°C until the next day in the following solution (in mmol/l): 103 NaCl, 5.4 KCl, 4.0 NaHCO 3, 1.5 NaH2PO4, 0.8 MgSO4, 5.1 glucose, 0.9 Na-pyruvate, 30 Na-isethionic acid, and 5.6 HEPES 5.6 with added 10 ml/l MEM vitamin solution (M6895, Sigma), 20 ml/l MEM essential amino acid solution (M5550, Sigma), and 10 ml/l MEM nonessential amino acid solution (M7145, Sigma) (18) . Human intrarenal arteries were mounted in a Halpern-Mulvany wire myograph (model 610, Danish Myo Technology, Aarhus, Denmark), and isometric force development was measured (PowerLab, AD Instruments, Colorado Springs, CO). Artery rings were incubated at 37°C in physiological salt solution, normalized, and allowed to equilibrate for 30 min. The viability of vascular smooth muscle and endothelial cells was tested by demonstrating contraction to phenylephrine (10 Ϫ6 mol/l) and relaxation to ACh (10 Ϫ6 mol/l), respectively. In human intrarenal arteries, the contraction induced by increasing concentrations of K ϩ (20, 40, 60, 80 , and 100 mmol/l) was tested in the absence and presence of the T-type blockers mibefradil (10 Ϫ7 mol/l) and NNC 55-0396 (3 ϫ 10 Ϫ6 mol/l, Sigma-Aldrich). Each concentration of K ϩ was applied for 5 min in the presence of phentolamin (10 Ϫ5 mol/l). Arterial blood pressure, heart rate, GFR, and renal plasma flow. Mice were anesthetized (100 mg/kg ketamine and 10 mg/kg xylazine). For measurements of arterial blood pressure and infusions of drugs, catheters consisting of a micro-renathane tip connected to polyethylene tubing were placed in the femoral artery and vein, respectively, and exteriorized through a subcutaneous tunnel from the groin to the back of the neck (3, 16) . In short, the catheters was filled with heparin solution (100 IU/ml in isotonic glucose) and attached to a swivel, enabling the mice to move freely. For analgesia, mice were given subcutaneous injections of Temgesic [buprenorphinum (0.3 mg/ml, 3.75 mg/kg)]. Mice recovered for 5 days before continuous measurements of mean arterial pressure (MAP) and heart rate (HR) for 4 days. The arterial line was connected to a pressure transducer (Föhr Medical Instruments, Hessen, Germany). Data were collected using LabView software (National Instruments, Austin, TX).
GFR was measured based on a constant infusion of inulin (25) . Sinistrin [inutest (25%, 10 l/h)] was infused by connecting the venous catheter to an infusion pump (Electronic shop, University of Southern Denmark). The infusion lasted for 24 or 96 h to achieve steady state, and a blood sample (100 l) was withdrawn from the arterial catheter at both time points. The plasma inulin concentration was determined by spectrophotometry with a modified version of the method of Gabel et al. (13) . The inulin concentration was quantified by reaction by inulinase (Sigma-Aldrich). Inulin was hydrolyzed to fructose, which was converted to sorbitol by sorbitol dehydrogenase. The amount of NADH consumed in the process is proportional to the amount of inulin in the sample. NADH concentrations were measured by spectrophotometry at 340 nm (Versa Max microplate reader, Molecular Devices). GFR was calculated as the inulin infusion rate divided by the plasma inulin concentration.
In other experiments, PAH clearance was used as an estimate of renal plasma flow. PAH (20% in saline, 10 l/h, Merck) was infused continuously for 24 and 96 h, and two blood samples (100 l) was taken at both time points. The experiment was repeated in WT mice using 10% PAH in saline to verify that the tubular secretion maximum was not reached. Blood samples were centrifuged, and plasma was collected and stored at Ϫ80°C. PAH in plasma was measured by a colorimetric reaction with dimethylaminocinnamaldehyde solution in an acidic environment. The intensity of the color generated was measured at 545 nm after 15-30 min of incubation. Renal plasma flow was calculated as the PAH infusion rate divided by the plasma PAH concentration at steady state, during which the infusion rate equals the excretion rate.
Statistical analysis. Data are presented as means Ϯ SE. Significance of changes was calculated by two-way ANOVA with a Bonferroni reduction for multiple comparisons and Student's t-test for comparison of two groups. P values of Ͻ0.05 were considered significant. Fig. 2C ). K ϩ (30 mmol/l) induced a significant constriction after 3 min of administration to efferent arterioles from Ca v 3.2 Ϫ/Ϫ mice, whereas no significant constriction was observed in WT mice (Fig. 2D) .
RESULTS
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Ca v 3.1 mice. The involvement of Ca v 3.1 in the regulation of baseline renal perfusion and GFR was tested in Ca v 3.1 Ϫ/Ϫ and WT mice. Values of GFR were not significantly different (Fig.  3A) . However, renal plasma flow was significantly elevated compared with WT mice (2.0 Ϯ 0.1 vs. 1.5 Ϯ 0.1 ml·min Ϫ/Ϫ mice, respectively (n ϭ 6), with a pronounced circadian rhythm in both genotypes (Fig. 4 , A and C); there was no significant difference between sexes. HRs in WT and Ca v 3.1 Ϫ/Ϫ mice averaged 623 Ϯ 19 and 592 Ϯ 24 beats/min, respectively (Fig. 4, B and D) . In male mice, HR was attenuated significantly in Ca v 3.1 Ϫ/Ϫ mice compared with WT mice. Female mice had significantly higher HRs than male mice in both genotypes (Fig. 4D) .
The increase in renal plasma flow could be due to a decrease in vascular resistance in the afferent and/or efferent arteriole. (Fig. 5A) . K ϩ at 30 mmol/l mediated the same degree of constriction in both Ca v 3.1 Ϫ/Ϫ and WT animals (Fig. 5B) . In efferent arterioles, eight individual experiments testing the effect of K ϩ showed a concentration-dependent constriction with EC 50 values of 17 mmol/l in WT animals and 19 mmol/l in Ca v 3.1 Ϫ/Ϫ animals ( Fig. 5C) , showing no significant difference between WT and Ca v 3.1 Ϫ/Ϫ animals. The time courses of the constriction in response to 30 mmol/l K ϩ were indistinguishable (Fig. 5D) .
Human arteries. The functional involvement of T-type Ca 2ϩ channels was tested in isolated human intrarenal arteries in a myograph setting after depolarization. The K ϩ concentration dependently contracted human intrarenal artery rings with an EC 50 value of 36 mmol/l. Administration of mibefradil in concentrations specific for T-type Ca 2ϩ channels significantly inhibited the contraction induced by 20 mmol/l K ϩ (Fig. 6A ). Another T-type antagonist, NNC 55-0396, also inhibited the contraction significantly; however, this effect occurred at all K ϩ concentrations (Fig. 6B) .
DISCUSSION
The present results demonstrate markedly different renal hemodynamic effects of absence of Ca v 3.2 or Ca v 3.1 at similar average arterial blood pressure. The data support the conclusion that Ca v 3.2 preferentially lowers resistance in the efferent arteriole, thereby affecting GFR, as Ca v 3.2 Ϫ/Ϫ animals had increased contractile responses of the efferent arteriole in response to depolarization and increased GFR with no significant change in plasma flow. In contrast, deletion of Ca v 3.1 channels increased renal plasma flow, whereas GFR was not changed measurably. That could be in agreement with an equal in contractility between afferent arterioles from WT and knockout (KO) animals, although a transient constriction was observed in some Ca v 3.2 Ϫ/Ϫ mice at the lowest K ϩ concentration. This supports the suggestion that the T-type Ca 2ϩ channel subtype Ca v 3.2 mediates the secondary dilatation after depolarization-induced constriction of the mouse perfused cortical efferent arteriole (36) . In agreement, inhibition of Ca v 3.2 by Ni 2ϩ at low concentrations potentiates the constriction by changing it from a transient response to a sustained response. Coronary blood vessels from Ca v 3.2 Ϫ/Ϫ mice show reduced relaxation after administration of ACh and nitroprusside (8) . Furthermore, the dilatation of perfused efferent arterioles is blocked by inhibition not only of Ca v 3.2 but also of eNOS, suggesting that T-type Ca v 3.2 channels and NO release are involved in the vasodilatation (36) . The increased contractility of efferent arterioles from Ca v 3.2 Ϫ/Ϫ mice could account for the observed increase in GFR by elevating filtration pressure. This would suggest that under normal physiological conditions, Ca v 3.2 channels in postglomerular arterioles mediate a dilatation that contributes to lower glomerular pressure. The renal plasma flow was not significantly changed, and MAP was not affected by lack of Ca v 3.2 channels. This is in agreement with previous recordings of systolic blood pressure using tail cuffs (10) . Changes in blood pressure could therefore not account for the increased GFR in KO animals. Furthermore, HR was not different between genotypes, suggesting that it is mainly Ca v 3.1 channels that are involved in regulating HR, as observed in the present study and in a previous study by Mangoni et al. (30) .
For Ca v 3.1 channels, the present in vivo data are in agreement with previous in vivo pharmacological data compatible with important effects of T-type Ca 2ϩ channels on renal hemodynamics. In anesthetized dogs, the T-type blocker mibefradil increased renal blood flow with no significant effect on GFR, suggesting balanced effects on afferent and efferent arterioles, whereas L-type blockage (with nifedipine) increased both renal plasma flow and GFR, suggesting a preferential afferent effect. Similarly, in spontaneously hypertensive rats, T-type blockade increased renal plasma flow more than GFR, resulting in a decrease in the filtration fraction (43) . The increase in renal blood flow without an increase in GFR in response to T-type blockade has been suggested to be due to dilatation of the efferent arteriole. An in vivo study (23) using a camera probe inserted directly into the kidney revealed a relative dilation of the efferent arteriole larger than that of the afferent arteriole after administration of the T-type antagonist mibefradil, and, in agreement, T-type antagonists have been demonstrated to dilate efferent arterioles in vitro (4, 20, 21, 35, 36) . However, in the present study, K ϩ -induced contractility responses of afferent and efferent arterioles of Ca v 3.1 Ϫ/Ϫ mice were not significantly different compared with WT mice. This is in disagreement with previous pharmacological studies (15, 22) showing an effect of a T-type blocker on arteriolar contractility.
The different responses in vivo with increased renal blood flow in Ca v 3.1 Ϫ/Ϫ mice with no apparent contribution of Ca v 3.1 in vitro in afferent arterioles could also be due to an attenuated sympathetic efferent nerve traffic that involves Ttype Ca 2ϩ channels. Chen and coworkers (7) investigated central sympathetic activity and T-type Ca 2ϩ channels in a preparation of brain stem-spinal cord-splanchnic sympathetic nerves. They demonstrated that Ca v 3.2 channels were required for maintaining central sympathetic outflow, and Ca v 3.1 had an inhibitory effect (7) . In a clinical study (19) , the T-type antagonist efonidipine reduced HR and sympathetic nervous activity. Renal nerve activity was not measured directly in Ca v 3.1 Ϫ/Ϫ animals, but since Ca v 3.1 Ϫ/Ϫ male mice displayed a lower HR, this would be compatible with attenuated sympathetic drive, although impaired automaticity in the sinus node also might be involved.
Furthermore, the in vivo data could be affected by a changed hormonal status as T-type blockers are involved in aldosterone release (9, 37) and the T-type antagonist efonidipine lowers aldosterone plasma levels in humans (34) . The aldosterone level in KO mice could therefore be expected to be lowered in KO animals. However, a potential lower aldosterone level is less likely as the reason for the observed increased GFR.
Both T-type Ca 2ϩ channels (Ca v 3.1 and Ca v 3.2) have been shown to be expressed in renal glomerular vessels (17) . In contrast to the expression data, a recent study (40) found no T-type Ca 2ϩ currents in either afferent or efferent arteriole myocytes, but T-type Ca 2ϩ currents were detected in tail arteries. T-type Ca 2ϩ currents have previously been measured in preglomerular vascular smooth muscle cells (14) . However, this discrepancy might be explained by the heterogeneous population of cells described by Gordienko et al. (14) . Ca 2ϩ blockers remain a popular first choice drug in the treatment of essential hypertension; however, the selectivity for different Ca 2ϩ channels differs, with some drugs affecting both L-and T-type Ca 2ϩ channels and others affecting only (n ϭ 7) . B: effect of NNC 55-0396 (NNC; T-type blocker) on K ϩ -induced dose-response contractions in human intrarenal arteries (n ϭ 6). All data are means Ϯ SE. *P Յ 0.001; **P Յ 0.01; ***P Յ 0.05. L-type Ca 2ϩ channels. Combined T-and L-type blockers have been suggested to have a therapeutic advantage over selective L-type blockers by providing renoprotection due to differential expression of Ca 2ϩ channels, with only T-type Ca 2ϩ channels (Ca v 3.1 and Ca v 3.2) expressed in efferent arterioles (15, 22, 42) . Clinical data support a renoprotective effect of combined T-and L-type blockers as it was concluded that treatment with a combined L-and T-type antagonist yields greater efficacy that a L-type antagonist in reducing blood pressure and proteinuria (32, 33, 38) . The Amlodipine-to-Benidipine Changeover study showed that benidipine (a combined L-and T-type antagonist) caused a larger reduction in blood pressure and proteinuria compared with L-type treatment by amlodipine (32) , suggesting a vasoconstrictor effect of T-type Ca 2ϩ channels on efferent arterioles. The present data show that it is imperative to discriminate between the effects of Ca v 3.1 and Ca v 3.2 since selective abrogated function of Ca v 3.2 leads to increased GFR. Therefore, antagonists with a Ca v 3.2 preference are less likely to mediate a renoprotective effect. The renoprotective effect of combined blockers in clinical studies could be due to a preferential action on Ca v 3.1, since an increased renal plasma flow and a tendency to decreased GFR was found in the absence of Ca v 3.1 channels in mice. T-type Ca 2ϩ channels are present in human resistance blood vessels (18) . The present study using pharmacological inhibitors shows that T-type Ca 2ϩ channels play a significant role in contractility of human intrarenal arteries. Increased tension at low K ϩ concentrations was significantly inhibited after both mibefradil and NNC 55-0396. This implies a graded contribution of Ca v channels with T-type effects at small deviations from the resting membrane potential. This is in agreement a recent study in T-type KO mice (5) and in a pharmacological study (1) showing the involvement of T-type Ca 2ϩ channels in response to small increases in perfusion pressure, which concluded that T-type Ca 2ϩ channels do play a role in the myogenic response (5) . In contrast to the present results with mibefradil, NNC 55-0396 inhibited the contraction induced at all K ϩ concentrations, which could be due to variations between patients or, more likely, that the drug also affects L-type Ca 2ϩ channels, as previously suggested (26) . Furthermore, an altered function of kidney vascular segments occurs in several pathological conditions, such as diabetes and hypertension (11, 39) . The present confirmation of a functional role for T-type Ca 2ϩ channels in the regulation of renal function suggests that T-type Ca 2ϩ channels could play a role under physiological conditions as well as in pathophysiological situations.
